Advertisements



We are Sorry, This Page doesn't Exist


Vertex completes enrollment of two Phase 3 studies of cystic fibrosis candidate

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 6th, 2018

Vertex"s Orkambi Wins EU Nod to Treat Cystic Fibrosis in Kids

Zacks.....»»

Category: topSource: redinewsJan 22nd, 2019

A Peninsula cell therapy company"s shares plunged 39% after its CEO resigned and the FDA raised manufacturing questions

Fardis had guided Iovance from being a little-know startup to the cusp of having an approved treatment. But the FDA request will set back its approval process by two years......»»

Category: topSource: bizjournalsMay 19th, 2021

Arrowhead announces improvement in fibrosis after ARO-AAT treatment in Patients

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 28th, 2021

Vertex Pharmaceuticals announces EC approval for Kaftrio label extension

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 28th, 2021

Vertex to study experimental gene-editing therapy as treatment for sickle cell, beta-thalassemia

Vertex Pharmaceuticals Inc. said Tuesday it plans to pay $1.1 billion to Crispr Therapeutics AG as part of a deal to test an experimental gene-editing therapy for sickle cell disease and transfusion-dependent beta-tha.....»»

Category: topSource: marketwatchApr 21st, 2021

NovoCure surges 65% to all-time high on upbeat review of its lung cancer treatment trial

"Pending regulatory approval, the recommended protocol adjustments could accelerate trial completion by more than a year," its CEO said. In this phot.....»»

Category: personnelSource: nytApr 13th, 2021

Syndax treatment of idiopathic pulmonary fibrosis granted FDA orphan status

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 8th, 2021

United Therapeutics gets another FDA approval for pulmonary hypertension therapy

United Therapeutics (NASDAQ: UTHR) has received another Food and Drug Administration approval for Tyvaso more than a decade after the agency first approved the therapy for treatment of pulmonary arterial hypertension.  The FDA approved a supplem.....»»

Category: topSource: bizjournalsApr 1st, 2021

Vertex receives Australian G approval for TRIKAFTA

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 24th, 2021

Translate Bio Shares Drop After Its mRNA-Based Cystic Fibrosis Candidate Did Not Improve Lung Function

Translate Bio Inc (NASDAQ: TBIO) revealed its second interim analysis from Phase 1/2 clinical trial evaluating MRT5005 in patients with cystic fibrosis (CF). Latest Ratings f.....»»

Category: blogSource: benzingaMar 18th, 2021

Vertex to begin Phase 1/2 trial of treatment for people with type 1 diabetes

Shares of Vertex Pharmaceuticals Inc. were down 0.2% in trading on Wednesday after the company said it started an early-stage clinical t.....»»

Category: dealsSource: nytMar 10th, 2021

Sarepta rallies 2% to $86.15 after winning FDA approval for DMD treatment

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 25th, 2021

Beyond Air receives grant for up to $2.17M from the Cystic Fibrosis Foundation

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 16th, 2021

Eloxx Pharmaceuticals" ELX-02 featured in Journal of Cystic Fibrosis

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 9th, 2021

Durect stock soars 34% after it gets FDA approval for surgical pain treatment

Shares of Durect Corp. gained 34.3% in premarket trading on Tuesday after the company said its drug,.....»»

Category: topSource: marketwatchFeb 2nd, 2021

FDA posts approval of Durect pain treatment Posimir

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 2nd, 2021

Why AzurRx BioPharma Is Trading Sharply Higher Today

AzurRx BioPharma (NASDAQ: AZRX) shares are trading higher Friday amid a surge in session volume for the day. On Thursday, the company announced it has started dosing in the mid-stage cystic fibrosis study of MS1819. read more.....»»

Category: blogSource: benzingaJan 22nd, 2021

The best acne treatments for every type of skin, according to dermatologists

The type of acne treatment you use has everything to do with the type of acne you have. We spoke to dermatologists about the best way to treat various types of acne, from blackheads to cystic bumps. There.....»»

Category: worldSource: nytJan 13th, 2021

Sumitovant unit Urovant gets FDA approval of Gemtesa NDA for OAB treatment

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 23rd, 2020